MAP2K1 is a potential therapeutic target in erlotinib resistant head and neck squamous cell carcinoma

Epidermal growth factor receptor (EGFR) targeted therapies have shown limited efficacy in head and neck squamous cell carcinoma (HNSCC) patients despite its overexpression. Identifying molecular mechanisms associated with acquired resistance to EGFR-TKIs such as erlotinib remains an unmet need and a...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Sci Rep
Main Authors: Jain, Ankit P., Patel, Krishna, Pinto, Sneha, Radhakrishnan, Aneesha, Nanjappa, Vishalakshi, Kumar, Manish, Raja, Remya, Patil, Arun H., Kumari, Anjali, Manoharan, Malini, Karunakaran, Coral, Murugan, Saktivel, Keshava Prasad, T. S., Chang, Xiaofei, Mathur, Premendu Prakash, Kumar, Prashant, Gupta, Ravi, Gupta, Rohit, Khanna-Gupta, Arati, Sidransky, David, Chatterjee, Aditi, Gowda, Harsha
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6906491/
https://ncbi.nlm.nih.gov/pubmed/31827134
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-019-55208-5
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados